Serum/plasma micro-RNA marker for detecting patients with mild cognitive impairment and application thereof

Abstract

The invention belongs to the field of biotechnology and neurocognitive and relates to a serum / plasma micro-RNA marker for detecting patients with mild cognitive impairment and an application thereof. The maker is any one or a combination of miR-206 and miRNA-132. The marker is applied in diagnosis of patients with mild cognitive impairment, and the marker is applied in preparation of a kit for diagnosis of patients with mild cognitive impairment. According to the application of the marker, content of serum / plasma miR-206 and / or miRNA-132 of a testee is detected by a real-time fluorescence quantitative polymerase chain reaction (Real-time PCR) method, and the content of the testee is compared with that of a normal cognitive subject to diagnose mild cognitive impairment. The screened miRNA marker has cognitive impairment specificity, is simple to operate diagnosis of mild cognitive impairment, has high sensitivity and is suitable for large-scale screening.

Description

technical field [0001] The invention relates to the application of serum / plasma microRNA (miRNA, referred to as miRNA), in particular to the detection of serum / plasma microRNA markers in patients with mild cognitive impairment and the application thereof, belonging to the technical fields of biotechnology and neurocognitive technology. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease that seriously threatens human health. Mild cognitive impairment (MCI) is a transitional state between Alzheimer's disease and normal aging. Studies have shown that 23% of patients with mild cognitive impairment will progress to Alzheimer's disease within 2 years, and 50% of patients will develop Alzheimer's disease within 4 years. Therefore, mild cognitive impairment is considered to be the most appropriate early intervention treatment for Alzheimer's disease stage. With the aging of the global population, the prevalence of mild cognitive impairment has in...

AI Technical Summary

Problems solved by technology

Although some cerebrospinal fluid markers (such as Aβ1-42, T-tau, P-tau, etc.) have been found (Alexopoulos et al., 2013), due to the traumatic nature of cerebrospinal fluid sample collection, clinical application must be strictly Master its indications and contraindications. In addition, the sensitivity and specificity of cerebrospinal fluid examination for the diagnosis of mild cognitive impairment are limited

Images